Kaipu Bio's wholly owned subsidiary Chaozhou Kaipu Biochemistry Company Limited has obtained a Class III medical device registration certificate issued by the National Medical Products Administration for its Chikungunya virus and dengue virus nucleic acid detection kit using fluorescent PCR. The registration certificate number is 20263401806, valid until August 30, 2031. The kit is used for in vitro qualitative detection of nucleic acids from both viruses in human serum or plasma samples, enabling simultaneous detection of two pathogens from a single sample, with the entire process completed within 70 minutes. Dengue fever and chikungunya are both acute infectious diseases transmitted by mosquitoes, with similar early symptoms. In April 2026, the National Disease Control and Prevention Administration included chikungunya in the management of Class B infectious diseases, requiring joint surveillance, testing, and prevention and control for both diseases. The company stated that this product enhances its product portfolio, aligns with its Nucleic Acid 99 strategic plan, and will have a positive impact on future operations, though actual sales and profit contributions remain uncertain.
Guangdong Hybribio Biotech Co LtdSubsidiary receives Class III registration for a new dual-pathogen detection kit, expanding product portfolio.
